OxyNov
Patrice Allibert, PhD, currently serves as the President and Chief Executive Officer of OxyNov, a medical device company in Québec City, specializing in the FreeO2 oxygen delivery monitoring apparatus, especially critical during the Covid-19 pandemic. In addition, Patrice Allibert holds several influential roles, including member of the Board of Directors for RNA Disease Diagnostics and Québec International, and task force member for the Canadian Antimicrobial Innovation Coalition. Experience includes presidency at MDx Consulting and board membership at Immunexpress, which focuses on sepsis diagnostics. Previously, Patrice Allibert was the CEO of GenePOC, successfully leading the company's sale for 160 million CAD, and held significant positions at FOLIA BioTech, the Canadian Institute of Health Research, and BD, where key innovations in molecular diagnostics were developed. Patrice Allibert obtained a Doctor of Philosophy in Molecular Biology from Université Joseph Fourier (Grenoble I) between 1982 and 1986.
This person is not in any teams
OxyNov
OxyNov is a young Canadian business focusing on clinical innovation and specialized in designing and commercializing innovative medical devices in the field of oxygen therapy and respiratory care. It was founded in 2009 by Professors Erwan L’Her (head of the Intensive Care Unit and INSERM researcher at the University Hospital of Brest) and FrançoisLellouche (intensivist and researcher at the IUCPQ -Quebec), further to a clinical research project having as an objective the development of a device automating the administration of oxygen therapy and the improvement of the application of this treatment on the daily basis